American Century Companies Inc Immuno Gen, Inc. Transaction History

American Century Companies Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$12.46 - $29.95 $10.4 Million - $25 Million	836,134 New	836,134 $24.8 Million
Q3 2023 Nov 13, 2023	SELL	$14.09 - $19.87 $17,006 - $23,983	-1,207 Reduced 0.17%	699,116 $11.1 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $2.63 Million - $14 Million	700,323 New	700,323 $13.2 Million
Q1 2022 May 11, 2022	SELL	$4.26 - $7.48 $55,247 - $97,008	-12,969 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$5.02 - $6.59 $10,105 - $13,265	-2,013 Reduced 13.44%	12,969 $74,000
Q2 2021 Aug 05, 2021	SELL	$5.79 - $8.6 $34,519 - $51,273	-5,962 Reduced 28.47%	14,982 $99,000
Q1 2021 May 14, 2021	BUY	$6.5 - $10.53 $66,956 - $108,469	10,301 Added 96.79%	20,944 $170,000
Q4 2020 Feb 12, 2021	BUY	$3.7 - $7.66 $39,379 - $81,525	10,643 New	10,643 $69,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

Stay updated on American Century Companies Inc with notifications on news.